



EOS imaging obtains marketing approval in Brazil

Paris, September 8, 2014 – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the Company has received approval from Brazilian National Health Surveillance Agency (ANVISA) to market the EOS® system in Brazil. The Company has now obtained authorization to market its technology in 33 countries.

Having been granted the necessary market approvals in Japan and Taiwan in October 2013 and April 2014, this additional approval is a significant milestone in the Group's international development and represents further recognition of EOS' technology.

Approval to market EOS' imaging technology in Brazil will enable the Company to deploy its initial marketing and commercial activities in the coming months and enter a growing Latin American market, which today represents 7 % of the global market for medical imaging equipment.

Marie Meynadier, CEO of EOS imaging, is delighted with this new authorization to market: *"This marketing approval in Brazil is yet another success for our Company. It will enable us to begin our commercial deployment in South America, a particularly dynamic region that is eager for innovation."*

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 33 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 90 sites and by more than 500,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of the Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI



**Next press release: revenue for the 3rd quarter of 2014:
22 October, 2014 (after market)**

Contacts:

Anne Renevot
CFO
Tel.: +33 (0)1 55 25 61 24
investors@eos-imaging.com

Newcap
Financial communication & Investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91 – eosimaging@newcap.fr

Newcap Media
Press Relations – Annie Florence Loyer
Tel.: +33 (0)1 44 71 00 12
afloyer@newcap.fr